Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 771-777

  Zou, Jian Jun ^a,b   Xie, Hong Guang ^b   Chen, Shao Liang ^b   Tan, Jie ^b   Lin, Ling ^b   Zhao, Ying Ying ^b   Xu, Hai Mei ^b   Lin, Song ^b   Zhang, Juan ^b   Wang, Guang Ji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Clopidogrel; CYP2C19; Platelet aggregation; Polymorphism; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ENZYME VARIANT;

ADULT; AGED; ANTIPLATELET EFFECT; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHINESE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ACTIVITY; DRUG ELUTING STENT; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEGRO; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT THROMBOSIS; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CORONARY THROMBOSIS; DNA; FEMALE; GENOTYPE; HEART DISEASES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STENTS; TICLOPIDINE; YOUNG ADULT;

EID: 84876713432     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1392-5     Document Type: Article

References (23)

1. Mega JL, Close SL, Wiviott SD, Shen L (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362
2. Xie HG, Zou JJ, Hu ZY (2011) Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. Pharmacol Ther 129:267-289
3. Simon T, Verstuyft C, Mary-Krause M (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375
4. Kuliczkowski W, Witkowski A, Polonski L (2009) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30:426-435
5. Paré G, Mehta SR, Yusuf S (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363:1704-1714
6. Pereillo JM, Maftouh M, Andrieu A (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288-1295
7. Savi P, Pereillo JM, Uzabiaga MF (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896
8. Trenk D, Hochholzer W, Fromm MF (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925-1934
9. Shuldiner AR, O'Connell JR, Bliden KP (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857
10. Sibbing D, Stegherr J, Latz W (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30:916-922
11. Xie HG (1997) Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects. Clin Pharmacol Ther 62:691-692
12. Xie HG, Kim RB, Wood AJ (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41:815-850
13. Li YG, Ni L, Brandt JT (2009) Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 20:316-327
14. Chang M, Dahl ML, Tybring G (1996) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363
15. Persson I, Aklillu E, Rodrigues F (1996) S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among E-thiopians. Pharmacogenetics 6:521-526
16. Bouman HJ, Parlak E, van Werkum JW, Breet NJ (2010) Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 8:482-488
17. Cutlip DE, Windecker S, Mehran R (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344-2351
18. Mauri L, Hsieh WH, Massaro JM (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020-1029
19. Chen SL, Santoso T, Zhang JJ (2011) A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions. J Am Coll Cardiol 57:914-920
20. Hulot JS, Bura A, Villard E (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247
21. Harmsze A, van Werkum JW, Bouman HJ (2010) Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 20:18-25
22. Jeong YH, Kim IS, Park Y (2010) Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated platelet inhibition by a double dose of clopidogrel according to gene polymorphism) study. JACC Cardiovasc Interv 3:731-741
23. Collet JP, Hulot JS, Pena A (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-317